-
Nuance Pharma’s Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment
•
China-based Nuance Pharma announced that it has received regulatory approval in Macau for its Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). This approval marks a significant milestone in the company’s efforts to expand the availability of Ohtuvayre in the Greater China region. Innovative Dual-Inhibitor TherapyEnsifentrine…
-
Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China
•
Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the Phase III ENHANCE-CHINA study (NCT05743075) for its drug Ohtuvayre (ensifentrine). This Phase III trial is a randomized, double-blind, placebo-controlled investigation assessing the efficacy and safety of Ohtuvayre over a 24-week period in adult patients diagnosed…
-
Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics
•
Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore arbitration court in a dispute with Canada’s Antibe Therapeutics (OTCMKTS: ATBPF). The arbitration centered on a February 2021 agreement where Nuance acquired development and commercial rights for Antibe’s otenaproxesul (ATB-346), an innovative pain relief drug…
-
Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau
•
China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to launch Bentrio nasal spray in Hong Kong and Macau. Under the agreement, DKSH HK will provide full-agency services, including key account management, marketing promotions, supply chain, and distribution for Bentrio Nasal Spray sales operations in…
-
Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China
•
China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct both Phase I and Phase III clinical trials for ensifentrine, a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Partnership and DevelopmentThe drug…
-
Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)
•
China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in a Phase I clinical study for its ketorolac for IV infusion (NTM-001), a non-opioid analgesic co-developed with US-based Neumentum Inc. Study DetailsThe Phase I study enrolled 16 healthy subjects, who have completed the 96-hour sample…
